Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Genet Test Mol Biomarkers. 2021 Feb;25(2):85-101. doi: 10.1089/gtmb.2020.0227.
Coronavirus disease 2019 (COVID-19) displays a broad spectrum of clinical presentations ranging from lack of symptoms to severe multiorgan system complications and death. Various laboratory assays have been employed in the diagnosis of COVID-19, including: nucleic acid-based tests; antigen tests; and serum testing for anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies. The disease can also be diagnosed based on suggestive clinical features and radiological findings. Until now, remdesivir is the only medication approved for the treatment of COVID-19 by the U.S. Food and Drug Administration (FDA); however, it is anticipated that several anti-SARS-CoV-2 monoclonal antibodies will gain soon approval. Other methods of treatment include supportive care directed toward treating the symptoms. Nevertheless, many studies have recently emerged, showing controversial preliminary results with the off-label medication hydroxychloroquine. Given that all results are still preliminary, including those seen by remdesivir, additional evidence and research are required to identify effective medications that are broadly effective and well tolerated. Importantly, two RNA-based vaccines have recently gained approval from Pfizer and Moderna, with many others still in clinical trials. This article reviews various aspects of COVID-19, including its epidemiology; its evolution and mutational spectrum; and its clinical dynamics, symptoms and complications, diagnosis, and treatment.
新型冠状病毒病 2019(COVID-19)表现出广泛的临床特征,从无症状到严重多器官系统并发症和死亡不等。已经采用了各种实验室检测方法来诊断 COVID-19,包括:基于核酸的检测、抗原检测以及针对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)抗体的血清检测。该疾病还可以根据提示性临床特征和影像学发现进行诊断。到目前为止,瑞德西韦是美国食品和药物管理局(FDA)唯一批准用于治疗 COVID-19 的药物;然而,预计几种抗 SARS-CoV-2 单克隆抗体将很快获得批准。其他治疗方法包括针对症状的支持性治疗。然而,最近出现了许多研究,显示了抗疟药羟氯喹的初步结果存在争议。鉴于所有结果仍处于初步阶段,包括瑞德西韦的结果,需要更多的证据和研究来确定广泛有效且耐受良好的有效药物。重要的是,辉瑞公司和 Moderna 公司最近批准了两种基于 RNA 的疫苗,而许多其他疫苗仍在临床试验中。本文综述了 COVID-19 的各个方面,包括其流行病学、演变和突变谱以及临床动态、症状和并发症、诊断和治疗。